KNSA (Kiniksa Pharmaceuticals International) Inventories, Raw Materials & Components: $10.4 Mil (As of Mar. 2026)


KNSA Kiniksa Pharmaceuticals International PLC KNSA
56 GF Score
Price $59.14
GF Value $47.92
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is Kiniksa Pharmaceuticals International Inventories, Raw Materials & Components?

Kiniksa Pharmaceuticals International KNSA +4.06% 56 Inventories, Raw Materials & Components is $10.4 Mil as of Mar. 2026. GuruFocus rates KNSA with a GF Score™ of 56/100 and a GF Value™ of $47.92 (Modestly Overvalued). The stock has 4 warning signs investors should review.

Kiniksa Pharmaceuticals International's inventories, raw materials & components for the quarter that ended in Mar. 2026 was $10.4 Mil.

Kiniksa Pharmaceuticals International's quarterly raw materials increased from Sep. 2025 ($0.0 Mil) to Dec. 2025 ($10.0 Mil) and increased from Dec. 2025 ($10.0 Mil) to Mar. 2026 ($10.4 Mil).

Kiniksa Pharmaceuticals International's annual raw materials increased from Dec. 2023 ($0.0 Mil) to Dec. 2024 ($10.0 Mil) but then declined from Dec. 2024 ($10.0 Mil) to Dec. 2025 ($10.0 Mil).

Kiniksa Pharmaceuticals International Inventories, Raw Materials & Components Historical Data

* Premium members only.

The historical data trend for Kiniksa Pharmaceuticals International's Inventories, Raw Materials & Components can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kiniksa Pharmaceuticals International Inventories, Raw Materials & Components Chart

Kiniksa Pharmaceuticals International Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Inventories, Raw Materials & Components
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 9.97 9.97

Kiniksa Pharmaceuticals International Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Inventories, Raw Materials & Components Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 9.97 10.45
KNSA
56GF Score
Kiniksa Pharmaceuticals International PLC KNSA
Inventories, Raw Materials & Components is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kiniksa Pharmaceuticals International Inventories, Raw Materials & Components Calculation

Materials and components scheduled for use in making a product.

What does a Inventories, Raw Materials & Components of $10.4 Mil mean?
Kiniksa Pharmaceuticals International (KNSA) has a Inventories, Raw Materials & Components of $10.4 Mil as of Mar. 2026. Raw materials are the components a company uses for its main products. View historical data on Kiniksa Pharmaceuticals International and its competitors.
Is Kiniksa Pharmaceuticals International's Inventories, Raw Materials & Components too high?
Kiniksa Pharmaceuticals International's current Inventories, Raw Materials & Components is $10.4 Mil. Overall, Kiniksa Pharmaceuticals International has a GF Score™ of 56/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Kiniksa Pharmaceuticals International's Inventories, Raw Materials & Components compare to INDV and AMRX?
Kiniksa Pharmaceuticals International's Inventories, Raw Materials & Components of $10.4 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventories, Raw Materials & Components for a Drug Manufacturers company?
A good Inventories, Raw Materials & Components depends on the Drug Manufacturers industry context. However, Inventories, Raw Materials & Components should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventories, Raw Materials & Components mean?
A high Inventories, Raw Materials & Components can signal that a stock is expensive relative to its fundamentals. Raw materials are the components a company uses for its main products. View historical data on Kiniksa Pharmaceuticals International and its competitors. Kiniksa Pharmaceuticals International's current Inventories, Raw Materials & Components is $10.4 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kiniksa Pharmaceuticals International stock overvalued right now?
Based on GuruFocus' analysis, Kiniksa Pharmaceuticals International (KNSA) is currently considered Modestly Overvalued. The stock's GF Value™ is $47.92, compared to a current price of $59.14 — trading 23.4% above its estimated fair value. The current Inventories, Raw Materials & Components is $10.4 Mil. Kiniksa Pharmaceuticals International's overall GF Score™ is 56/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventories, Raw Materials & Components calculated?
Inventories, Raw Materials & Components is calculated from a company's financial statements. For Kiniksa Pharmaceuticals International (KNSA), the current Inventories, Raw Materials & Components is $10.4 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Kiniksa Pharmaceuticals International (KNSA) Overvalued in 2026?

Based on GuruFocus' analysis, Kiniksa Pharmaceuticals International stock appears to be overvalued. The current stock price of $59.14 is trading 23.4% above its estimated GF Value™ of $47.92. GuruFocus considers Kiniksa Pharmaceuticals International to be Modestly Overvalued.

Key valuation signals for KNSA:

  • Inventories, Raw Materials & Components: $10.4 Mil
  • GF Value™: $47.92 vs. price of $59.14 (23.4% above fair value)
  • GF Score™: 56/100 with 4 warning signs

No single metric tells the full story. See the KNSA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Kiniksa Pharmaceuticals International Business Description

Address 105 Piccadilly, Second Floor, London, GBR, W1J 7NJ
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.
56GF Score

Get the complete analysis for KNSA

Inventories, Raw Materials & Components is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$59.14
Price
$47.92
GF Value